<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62205">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080936</url>
  </required_header>
  <id_info>
    <org_study_id>FVIE_M2W</org_study_id>
    <nct_id>NCT02080936</nct_id>
  </id_info>
  <brief_title>Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD</brief_title>
  <acronym>M2W</acronym>
  <official_title>Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Fontalvie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Fontalvie</source>
  <oversight_info>
    <authority>France: Ministère de l'Enseignement supérieur et de la Recherche</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral muscle mass and strength are relevant indicators of COPD survival. Current
      guidelines recommend to assess muscle strength only in muscle wasted patients. However, a
      recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp.
      Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In
      clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess
      muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary
      rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of
      muscle wasting clinical signs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Muscle wasting in COPD patient</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle weakness in COPD patient</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">138</enrollment>
  <condition>COPD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients from &quot;Clinique du Souffle La vallonie&quot; and &quot;Clinique du Souffle La Solane&quot;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have got FFMI (bioimpedance)

          -  Patients who have done quadriceps muscle strenght evaluation

        Exclusion Criteria:

          -  Patients without FFMI

          -  Patients without quadriceps muscle strenght
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique du Souffle La Vallonie</name>
      <address>
        <city>Lodeve</city>
        <zip>34700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Experimental approaches</keyword>
  <keyword>Peripheral muscle Keyword</keyword>
  <keyword>Rehabilitation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
